Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
bevacizumab + triamcinolone acetonide
- Development stage
- Unknown
- Lead developer
- Hayatabad Medical Complex
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Monoclonal Antibodies → Antibody-Based Therapeutics
- Administration
- Ophthalmic
01
Overview
This combination therapy consists of bevacizumab, a recombinant humanized monoclonal antibody that inhibits vascular endothelial growth factor (VEGF), and triamcinolone acetonide, a synthetic corticosteroid with anti-inflammatory and anti-angiogenic properties. The combination is administered via intravitreal injection to treat macular edema secondary to central retinal vein occlusion (CRVO). Bevacizumab works by binding to VEGF-A, preventing its interaction with receptors and thereby reducing vascular permeability and angiogenesis. Triamcinolone acetonide reduces inflammation and stabilizes the blood-retinal barrier. This specific combination was evaluated by the Hayatabad Medical Complex in a clinical trial to compare its efficacy against bevacizumab monotherapy.
- Brand names
- AvastinKenacort-A
- Other names
- bevacizumab and triamcinolone acetonide combination
02
Targets
GR (Glucocorticoid receptor)VEGFA (Vascular endothelial growth factor A)
Beyond the preview
Go deeper on bevacizumab + triamcinolone acetonide.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on bevacizumab + triamcinolone acetonide.